Aktis Oncology Inc.: Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue ...

Data to be presented across two posters at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingCombined results evaluating AKY-2519 across several B7-H3 expressing tumor types, includi ...

Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7 ...

Data to be presented across two posters at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingCombined results evaluating ...
world-nuclear-news

TerraPower starts work on flagship Ac-225 facility

TerraPower Isotopes announced it has broken ground in the Bellwether District of Philadelphia on what it claims will be the world's largest actinium-225 manufacturing facility. (Image: TerraPower) The ...
Yahoo Finance

TerraPower Isotopes Breaks Ground on World's Largest Actinium-225 Manufacturing Facility in Philadelphia

$450 million East Coast flagship cGMP facility will increase Ac-225 production capacity twentyfold, supporting the next generation of cancer therapies PHILADELPHIA, May 6, 2026 /PRNewswire/ -- ...
Washington Daily News

Ac-225 PSMA Therapy: What a Successful Actinium-225 Case Can Show Patients

Advanced or metastatic prostate cancer often requires a comprehensive treatment approach. Radioligand therapy is one of the options considered when the tumor shows PSMA expression and the patient ...
Morningstar

Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer

Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary efficacy of ...
Medscape

PSMA PET: Prostate Cancer Staging Revolution Awaits RCT Data

Over the past decade or so, prostate-specific membrane antigen (PSMA) PET/CT has increasingly replaced conventional imaging in men with biochemical recurrence after radical prostatectomy. PSMA PET/CT ...
FiercePharma

Novartis taps Niowave for long-term supply of radiopharmaceutical isotope

The clamor for radioisotopes has continued into the new year, with Novartis inking a deal with radiopharmaceutical producer Niowave to supply the pharma giant with the specialized ingredient ...
Morningstar

BIOEMTECH and NorthStar Medical Radioisotopes Announce Strategic Supply Agreement for Actinium-225 to Support Preclinical Radiopharmaceutical Research

BIOEMTECH, a developer of high-resolution PET and SPECT imaging systems for preclinical and translational research, today announced a strategic supply agreement with NorthStar Medical Radioisotopes ...
News Medical

PSMA PET/CT scans may predict prostate cancer recurrence, guide treatment

New research in the February 2026 issue of JNCCN-Journal of the National Comprehensive Cancer Network found that incorporating information from prostate-specific membrane antigen (PSMA) PET/CT scans ...
BioSpace

NorthStar Medical Radioisotopes Confirms Successful Routine Commercial-scale Ac-225 Production

First in industry to produce commercial-scale non-carrier-added (n.c.a) Actinium-225 using electron-accelerator technology Product demonstrate high radionuclidic purity profile ensuring consistent ...